Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2025-11-27
Disclosure Type: Execution of Single Sales/Supply Contract (Correction)
💡 3-Second Summary
Samsung Biologics has extended the confidentiality period regarding the contract timeline for its medicine contract manufacturing (CMO) agreement with Ichnos Sciences, signed in 2018, from the end of 2025 to December 31, 2026, at the client’s request. The contract, valued at approximately KRW 16.3B, includes clauses that allow the minimum guaranteed contract amount to scale up depending on the client’s product development success or demand increases.
📊 1. [Summary of Core Disclosure Content and Major Figures]
- Reason for Amendment: Extension of disclosure deferment period (maintenance of business confidentiality regarding contract period) at the client’s request.
- Contract Amount: KRW 16,250,627,156 (Approximately KRW 16.3B)
- This figure represents the reported sales value of USD 15,097,201 applied with the initial standard trading exchange rate of 1,076.40 KRW/USD as of June 1, 2018.
- Ratio to Sales: 3.50% (Compared to the recent annual sales of KRW 464.6B from the 2017 individual financial statements).
- Counterparty: Ichnos Sciences
- Contract Period: September 5, 2017 (Start Date) to Unspecified End Date (The timeline remains confidential due to business secrecy until December 31, 2026, subject to change).
- Key Conditions: No contract deposit or down payment.
- Other Investment Considerations:
- This filing reflects the addition of supplementary production volumes agreed upon on November 5, 2019, under the overarching ‘Master Service Agreement’ for the first specific contract product.
- If the client successfully develops the contracted product, the minimum guaranteed contract amount may increase to USD 66,442,601.
- If the client’s demand increases, the minimum guaranteed contract amount may be raised further upon mutual consultation.
📈 2. [Expert View: What This Disclosure Means for Investors]
- Adjustment of Administrative Timelines: This correction disclosure formalizes that the disclosure deferment period regarding the contract timeline has been adjusted to December 31, 2026, based on the client’s request. Since this filing strictly reports administrative changes to the disclosure schedule, investors should focus on these factual modifications rather than expanding them into assumptions about actual contract execution rates or operational performance.
- Implications of Extending Confidentiality: Extending the business confidentiality period to 2026 regarding the contract timeline is an administrative step taken to meet the client’s operational security needs. While this indicates that the procedural terms have been extended without cancellation, the actual operational progress and potential future adjustments of the contract remain subject to ongoing tracking through subsequent regulatory disclosures.
- Potential Capacity for Contract Amount Modification: The clause stating that the “minimum guaranteed contract amount could increase to USD 66,442,601 upon development success” introduces a potential opportunity for future adjustment in the total value. However, because the disclosure does not explicitly state the specific causes for performance changes or provide guaranteed figures, investors are encouraged to treat this as a potential impact rather than an absolute projection of guaranteed growth.
📝 Editor’s Comment (by K-STOCK Editor)
This regulatory correction from Samsung Biologics provides objective documentation that the confidentiality timeline regarding the contract period for a CMO agreement with Ichnos Sciences has been rescheduled to the end of 2026. In the global biopharmaceutical market, adjusting disclosure deferment periods to protect a client’s corporate information and product development stages is a standard administrative procedure. From an investor’s standpoint, while the potential clause for contract value scaling up to approximately USD 66.44M upon development milestones should be recognized, it is critical to view this filing purely as an administrative adjustment of schedules rather than a definitive guarantee of contract fulfillment or backlog stability. Investors should utilize this update primarily as an objective indicator of modified contract terms.
📢 Disclaimer and Source Information
Source: This content was newly structured and written based on official submission data from the Financial Supervisory Service Electronic Disclosure System (DART).
Investment Risk Notice: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
